Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758893 | 0.96 | ALDH1A1 (0.35) | ALDH1A1TP53TSHR | |
| SCHEMBL5427 | 0.96 | ALDH1A1 (0.35) | ALDH1A1TP53TSHR | |
| Ammonia Solution, Strong SCHEMBL18983394 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Hydrochloric Acid SCHEMBL27804397 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Bromide SCHEMBL28542014 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Water SCHEMBL28635166 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Hydrogen Sulfide SCHEMBL28330299 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| SCHEMBL926990 | 0.90 | ALDH1A1 (0.32) | ALDH1A1TP53TSHR | |
| Bicarbonate SCHEMBL15874485 | 0.90 | ALDH1A1 (0.39) | ALDH1A1TP53TSHR | |
| Ethylene SCHEMBL29034469 | 0.90 | ALDH1A1 (0.32) | ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312330-B2 | 1-((S)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | PHARVARIS GMBH (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-3983402-B1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20220135542-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| EP-3983402-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | Pharvaris GmbH (CH) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020234479-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312330-B2 | 1-((S)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | BDKRB2, BDKRB1, BRCA1 | ALDH1A1 2596/4885TP53 1023/4885TSHR 1518/4885 |
| US-20220135542-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | BDKRB2, BDKRB1, BRCA1 | ALDH1A1 2571/4885TP53 1025/4885TSHR 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.